Showing 6231-6240 of 9662 results for "".
Antihistamine Selection and Measuring Disease Control in Chronic Spontaneous Urticaria
https://practicaldermatology.com/programs/practical-dermatology/antihistamine-selection-and-measuring-disease-control-in-chronic-spontaneous-urticaria/84984/Michelle Tarbox, MD, shares practical strategies for managing chronic spontaneous urticaria, including antihistamine selection, dose escalation, and the use of patient-reported outcome measures to assess disease activity and treatment effectiveness.Advancing Digital Medicine in Dermatology
https://practicaldermatology.com/programs/practical-dermatology/advancing-digital-medicine-in-dermatology/18187/The Digital Medicine Society (DiME) is a global nonprofit dedicated to advancing the ethical, effective, equitable, and safe use of digital medicine to redefine health care and improve lives. DiME recently released a new set of resources, available at www.dimesociety.org/access-resources/, to advancEvolving Atopic Dermatitis Therapeutic Capabilities
https://practicaldermatology.com/videos/c-suite-chats/evolving-atopic-dermatitis-therapeutic-capabilities/67100/J. Mark Jackson, MD, FAAD, Senior Vice President, Clinical Development for Evommune, discusses the importance of improved efficacy and safety for underserved patients with atopic dermatitis.Treatment Approaches for Psoriatic Arthritis
https://practicaldermatology.com/programs/practical-dermatology-il-17-journal-club/treatment-approaches-for-psoriatic-arthritis/48809/Naeim T. Issa, MD, PhD, FAAD, joins Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, to discuss the Mediterranean Journal of Rheumatology article “Emerging Targets in Psoriatic Arthritis: Dual IL-17A/F and Selective TYK2 Inhibition in a Clinical Perspective.”Addressing the Psychologic Impact of Atopic Dermatitis on Pediatric Patients
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/addressing-the-psychologic-impact-of-atopic-dermatitis-on-pediatric-patients/37174/Elizabeth Lippner, MD, MA, Attending Physician in the Division of Allergy and Immunology and Assistant Professor of Pediatrics at Northwestern University Feinberg School of Medicine, describes the psychologic impact of atopic dermatitis on children and how clinicians can address these issues.Beyond Skin Clearance: What Patient-Reported Outcomes Reveal in Atopic Dermatitis
https://practicaldermatology.com/programs/practical-dermatology-updates-in-atopic-dermatitis/beyond-skin-clearance-what-patient-reported-outcomes-reveal-in-atopic-dermatitis/57286/Michael Lewitt, MD, FAAD, explains how patient-reported outcomes capture itch, sleep, pain, treatment experience, and other dimensions of atopic dermatitis that clinical measures may miss.DermWireTV: Atopic Dermatitis Pipeline Watch, a Potential New Skin Cancer Treatment; Demystifying Itch, and the Premiere of PA Perspectives
https://practicaldermatology.com/topics/practice-management/dermwiretv-atopic-dermatitis-pipeline-watch-a-potential-new-skin-cancer-treatment-demystifying-itch-and-the-premiere-of-pa-perspectives/20228/Escient Pharmaceuticals, Rapt Therapeutics, and Connect Biopharma each report positive results from early clinical studies in AD. Finnish researchers discover a potential treatment for cutaneous squamous cell carcinoma in an existing chemotherapy drug. Research out of Harvard Medical School links ecLet's Talk About Rosacea and Acne
https://practicaldermatology.com/conferences/scale-2023/acne-and-rosacea/20188/Hilary Baldwin, MD, shares pearls for treating papopustular rosacea, vascular rosacea, and acne.Weighing the Role of Network Meta-analysis for Choosing Biologic Therapies in Psoriatic Disease
https://practicaldermatology.com/programs/practical-dermatology/weighing-the-role-of-network-meta-analysis-for-choosing-biologic-therapies-in-psoriatic-disease/18189/There’s no paucity of studies for biologic therapies used to treat psoriatic disease, but the number of head-to-head trials comparing these agents is limited. Enter network meta-analysis, a statistical methodology that has emerged over the past few years to compare medication. Philip Mease, MD, a clClinical Conversations: A conversation with Dr Angela Lamb, a dermatologist and professor in New York, New York
https://practicaldermatology.com/programs/nemluvio-peer-network/clinical-conversations-a-conversation-with-dr-angela-lamb-a-dermatologist-and-professor-in-new-york-new-york/37237/Dr Angela Lamb discusses her approach to treating prurigo nodularis (PN) and atopic dermatitis (AD). She’ll explain how NEMLUVIO®, the first and only neuroimmune-targeted therapy that blocks IL-31RA, targets both immune and neuronal pathways and addresses chronic itch, inflammation, and barrier disr